Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 9/2020

01-09-2020 | Computed Tomography | Gynecologic Oncology

The Impact of Sarcopenia and Low Muscle Attenuation on Overall Survival in Epithelial Ovarian Cancer: A Systematic Review and Meta-analysis

Authors: Veronica McSharry, MSc, Amy Mullee, PhD, Lara McCann, MSc, Ailin C. Rogers, MB PhD, Mary McKiernan, BSc (Hons), Donal J. Brennan, MB PhD

Published in: Annals of Surgical Oncology | Issue 9/2020

Login to get access

Abstract

Background

Sarcopenia is defined as a progressive loss of skeletal muscle mass, strength and physical performance. Myosteatosis is an increase of intra- and intermuscular fat and can be measured radiologically by muscle attenuation. The study aim was to perform a systematic review and meta-analysis on the prognostic potential of sarcopenia and low muscle attenuation in relation to 3-year survival rates (3YSR) and 5YSR in epithelial ovarian cancer (EOC).

Methods

A systematic literature search was conducted using the databases Ovid Medline, EMBASE, and Scopus, using PRISMA guidelines, from inception to 10th of May 2019. Studies evaluated the prognostic potential of sarcopenia and low muscle attenuation on 3YSR and 5YSR in EOC. Quality assessment of included studies was performed using the Methodological Index for Non-Randomised Studies criteria.

Results

A comprehensive search of databases resulted in the identification of 2194 studies, resulting in 1695 citations meeting the inclusion criteria. Six studies were included for systematic review. Sarcopenia was not significantly associated with improved 3YSR (OR 1.7, 95% CI 0.8–3.5, p = 0.15) or 5YSR (OR 1.8, 95% CI 1.0–3.2, p = 0.07) in meta-analysis. Normal muscle attenuation was associated with a favourable 3YSR (OR 3.0, 95% CI 2.0–4.5, p < 0.001) and 5YSR (OR 2.3, 95% CI 1.6–3.4, p < 0.001) compared to low muscle attenuation.

Conclusion

Our meta-analysis indicated normal muscle attenuation was significantly associated with improved 3YSR and 5YSR in patients with EOC. Sarcopenia was not significantly associated with 3YSR or 5YSR in patients with EOC.
Appendix
Available only for authorised users
Literature
1.
National Cancer Registry Ireland. Cancer in Ireland 1994–2017 with estimates for 2017–2019. Ireland: National Cancer Registry Ireland;2019.
2.
Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. Sep 11 2019.
3.
du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. Mar 15 2009;115(6):1234–44.PubMedCrossRef
4.
Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New Engl J Med. 2010;363(10):943–53.PubMedCrossRef
5.
Kumar A, Moynagh MR, Multinu F, et al. Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer. Gynecol Oncol. 2016 2016;142(2):311–6.
6.
Ryan AM, Prado CM, Sullivan ES, Power DG, Daly LE. Impact of weight loss and sarcopenia on response to chemotherapy, quality of life and survival. Nutrition. 2019;67–8.
7.
Laky B, Janda M, Bauer J, Vavra C, Cleghorn G, Obermair A. Malnutrition among gynaecological cancer patients. Eur J Clin Nutr. May 2007;61(5):642–6.PubMedCrossRef
8.
Balogun N, Forbes A, Widschwendter M, Lanceley A. Noninvasive nutritional management of ovarian cancer patients beyond intestinal obstruction. Int J Gynecol Cancer. 2012;22(6):1089–95.PubMedCrossRef
9.
Yim GW, Eoh KJ, Kim SW, Nam EJ, Kim YT. Malnutrition identified by the nutritional risk index and poor prognosis in advanced epithelial ovarian carcinoma. Nutr Cancer. 2016;68(5):772–9.PubMedCrossRef
10.
Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. The Lancet Oncology. 2011/05/01/2011;12(5):489–95.
11.
Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31.PubMedCrossRef
12.
Caan BJ, Meyerhardt JA, Kroenke CH, et al. Explaining the obesity paradox: the association between body composition and colorectal cancer survival (C-SCANS Study). Cancer Epidemiol. Biomarkers Prev. 2017;26(7):1008–15.
13.
Daly LE, Power DG, O’Reilly A, et al. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Brit J Cancer. 31 2017;116(3):310–7.PubMedCrossRef
14.
Prado CM, Cushen SJ, Orsso CE, Ryan AM. Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact. P Nutr Soc. 2016;75(2):188–98.CrossRef
15.
Daly LE, Ni Bhuachalla EB, Power DG, Cushen SJ, James K, Ryan AM. Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer. J Cachexia Sarcopeni. 2018;9(2):315–25.CrossRef
16.
17.
Martin L, Birdsell L, MacDonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 20 2013;31(12):1539–47.PubMedCrossRef
18.
Tachi Y, Kozuka A, Hirai T, et al. Impact of myosteatosis on skeletal muscle volume loss in patients with chronic liver disease. J Gastroenterol Hepatol. 27 2018.
19.
McSorley ST, Black DH, Horgan PG, McMillan DC. The relationship between tumour stage, systemic inflammation, body composition and survival in patients with colorectal cancer. Clin Nutr. 2018;37(4):1279–85.PubMedCrossRef
20.
Boer BC, de Graaff F, Brusse-Keizer M, et al. Skeletal muscle mass and quality as risk factors for postoperative outcome after open colon resection for cancer. Int J Colorectal Dis. 2016;31(6):1117–24.PubMedCrossRef
21.
Rodrigues CS, Chaves GV. Skeletal muscle quality beyond average muscle attenuation: a proposal of skeletal muscle phenotypes to predict short-term survival in patients with endometrial cancer. J Natl Compr Canc Ne. 2018;16(2):153–60.CrossRef
22.
Zhuang CL, Shen X, Huang YY, et al. Myosteatosis predicts prognosis after radical gastrectomy for gastric cancer: a propensity score-matched analysis from a large-scale cohort. Surgery. 2019;166(3):297–304.PubMedCrossRef
23.
Mourtzakis M, Prado CMM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl. Physiol. Nutr. Metab. 2008/10/01 2018;33(5):997–1006.
24.
Ryan AM, Power DG, Daly L, Cushen SJ, Bhuachalla EN, Prado CM. Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later. P Nutr Soc. 2016;75(2):199–211.CrossRef
25.
Moher D, Liberati A, Tetzlaff J, Altman DG, Grp P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7).
26.
Rutten IJG, Ubachs J, Kruitwagen RFPM, Beets-Tan RGH, Olde Damink SWM, Van Gorp T. Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer. J Cachexia Sarcopenia Muscle. 2017/08/01 2017;8(4):630–8.
27.
Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. Anz J Surg. 2003;73(9):712–6.PubMedCrossRef
28.
Aust S, Knogler T, Pils D, et al. Skeletal muscle depletion and markers for cancer cachexia are strong prognostic factors in epithelial ovarian cancer. PLoS ONE. 2015 2015;10(10):e0140403.
29.
Ataseven B, Luengo TG, du Bois A, et al. Skeletal muscle attenuation (sarcopenia) predicts reduced overall survival in patients with advanced epithelial ovarian cancer undergoing primary debulking surgery. Annals of Surgical Oncology. 2018;25(11):3372–9.PubMedCrossRef
30.
Bronger H, Hederich P, Hapfelmeier A, et al. Sarcopenia in advanced serous ovarian cancer. Int J Gynecol Cancer. 2017;27(2):223–32.PubMedCrossRef
31.
Rutten IJG, van Dijk DPJ, Kruitwagen RFPM, Beets-Tan RGH, Olde Damink SWM, van Gorp T. Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients. J Cachexia Sarcopenia Muscle. 2016 2016;7(4):458–66.
32.
Rutten IJG, Ubachs J, Kruitwagen RFPM, et al. The influence of sarcopenia on survival and surgical complications in ovarian cancer patients undergoing primary debulking surgery. Eur. J. Surg. Oncol. 2017 2017;43(4):717–24.
33.
Ubachs J, Ziemons J, Minis-Rutten IJG, et al. Sarcopenia and ovarian cancer survival: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2019;10(6):1165–74.PubMedPubMedCentralCrossRef
34.
Antoun S, Lanoy E, Iacovelli R, et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer. 2013;119(18):3377–84.PubMedCrossRef
35.
Gabiatti CTB, Martins MCL, Miyazaki DL, et al. Myosteatosis in a systemic inflammation-dependent manner predicts favorable survival outcomes in locally advanced esophageal cancer. Cancer Med. 2019;8(16):6967–76.PubMedPubMedCentralCrossRef
36.
van Dijk DPJ, Bakens MJAM, Coolsen MME, et al. Low skeletal muscle radiation attenuation and visceral adiposity are associated with overall survival and surgical site infections in patients with pancreatic cancer. J Cachexia Sarcopenia Muscle. 2017;8(2):317–26.PubMedCrossRef
37.
Blauwhoff-Buskermolen S, Versteeg KS, de van der Schueren MAE, et al. Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer. J Clin Oncol. 2016/04/20 2016;34(12):1339–44.
38.
Tan BHL, Birdsell LA, Martin L, Baracos VE, Fearon KCH. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clinical Cancer Research. 2009;15(22):6973.PubMedCrossRef
39.
Silver JK, Baima J. Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. American Journal of Physical Medicine & Rehabilitation. 2013;92(8):715–27.CrossRef
40.
Nelson G, Bakkum-Gamez J, Kalogera E, et al. Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations—2019 update. Int. J. Gynecol. Cancer. 2019:ijgc-2019-000356.
41.
Stephens NA, Skipworth RJE, Macdonald AJ, Greig CA, Ross JA, Fearon KCH. Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. J Cachexia Sarcopenia Muscle. 2011;2(2):111–7.PubMedPubMedCentralCrossRef
42.
Malietzis G, Johns N, Al-Hassi HO, et al. Low muscularity and myosteatosis is related to the host systemic inflammatory response in patients undergoing surgery for colorectal cancer. Annals of Surgery. 2016;263(2):320–5.CrossRef
43.
Miljkovic I, Cauley JA, Wang PY, et al. Abdominal myosteatosis is independently associated with hyperinsulinemia and insulin resistance among older men without diabetes. Obesity (Silver Spring). 2013;21(10):2118–25.PubMedCentralCrossRef
44.
Campbell K, Winters-Stone K, Patel A, et al. An executive summary of reports from an international multidisciplinary roundtable on exercise and cancer: evidence, guidelines, and implementation. Rehabilitation Oncology. 10/01 2019;37:144–52.
45.
Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36(1):11–48.PubMedCrossRef
46.
Guadagni M, Biolo G. Effects of inflammation and/or inactivity on the need for dietary protein. Current Opinion in Clinical Nutrition & Metabolic Care. 2009;12(6):617–22.CrossRef
47.
Ewaschuk JB, Almasud A, Mazurak VC. Role of n-3 fatty acids in muscle loss and myosteatosis. Applied Physiology, Nutrition, and Metabolism. 2014/06/01 2014;39(6):654–62.
48.
Thompson KL, Elliott L, Fuchs-Tarlovsky V, Levin RM, Voss AC, Piemonte T. Oncology Evidence-based nutrition practice guideline for adults. Journal of the Academy of Nutrition and Dietetics. 2017;117(2):297–310.e247.PubMedCrossRef
49.
Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. European Journal of Cancer. 2016;57:58–67.PubMedCrossRef
50.
Conrad LB, Awdeh H, Acosta-Torres S, et al. Pre-operative core muscle index in combination with hypoalbuminemia is associated with poor prognosis in advanced ovarian cancer. J. Surg. Oncol. 2018;117(5):1020–8.PubMedCrossRef
51.
Torres ML, Hartmann LC, Cliby WA, et al. Nutritional status, CT body composition measures and survival in ovarian cancer. Gynecol Oncol. 2013;129(3):548–53.PubMedCrossRef
52.
Mourtzakis M, Prado CMM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Applied Physiology, Nutrition, and Metabolism. 2008/10/01 2008;33(5):997–1006.
Metadata
Title
The Impact of Sarcopenia and Low Muscle Attenuation on Overall Survival in Epithelial Ovarian Cancer: A Systematic Review and Meta-analysis
Authors
Veronica McSharry, MSc
Amy Mullee, PhD
Lara McCann, MSc
Ailin C. Rogers, MB PhD
Mary McKiernan, BSc (Hons)
Donal J. Brennan, MB PhD
Publication date
01-09-2020
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 9/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08382-0

Other articles of this Issue 9/2020

Annals of Surgical Oncology 9/2020 Go to the issue

Breast Oncology

Evaluating the Long-Term Impact of a Cooperative Group Trial on Radiation Use and Adjuvant Endocrine Therapy Adherence Among Older Women

ASO Author Reflections

ASO Author Reflections: Uninsurance is Associated with Worse Outcomes Following Resection for Gastro-Entero-Pancreatic Neuroendocrine Tumors

ASO Author Reflections

ASO Author Reflections: Which is More Suitable for Surrogate Indicator of Gastric Cancer Patients’ Long-Term Prognosis: Lymph Nodes Examined Number or Lymph Node Noncompliance Rate?

Peritoneal Surface Malignancy

Assessment of the Surgical Workforce Pertaining to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the United States

ASO Author Reflections

ASO Author Reflections: Assessing the Outcomes of Liver Cancer Patients Undergoing Surgery Over the Last Decade—Are We Doing Better?

ASO Author Reflections

ASO Author Reflections: Assessing the Impact of Neoadjuvant Therapy: A Real View Perspective